ProSciento Appoints Dr. Kelvin Logan, Former Executive at INC Research and Quintiles, to its Board of Directors

"Kelvin is a highly accomplished leader in the global clinical R&D industry, and we are very pleased to have an individual of his business and leadership acumen join our Board of Directors," said Dr. Marcus Hompesch, ProSciento's CEO and Chairman of the Board. "With his extensive experience and track record in driving strategic growth in the CRO industry, he will bring valuable insight to ProSciento's Board as we continue our expansion into new geographies and additional capabilities."

Dr. Logan is a life sciences executive with more than 30 years' experience in the pharmaceutical and clinical research industry. He served as President of Europe, Asia and Latin America at INC Research, where he was instrumental in the expansion of INC Research's global operations and partnerships throughout Central, Western and Eastern Europe, Asia, Japan, Australia, South Africa, and Latin America. Prior to joining INC Research, Dr. Logan was Senior Vice President and Senior Partner at Quintiles. In this role, he oversaw Quintiles' clinical development services and operations in Europe for the CNS business unit and subsequently late phase clinical research. He also held leadership positions at Pharmaco LSR International, acquired by PPD in 1996.

"I'm extremely pleased to join ProSciento's Board of Directors, a group consisting of highly respected leaders representing significant scientific and operational achievements in clinical R&D and within the pharmaceutical industry," said Dr. Logan.  "ProSciento is uniquely positioned for growth in today's rapidly evolving clinical R&D industry as a therapeutically focused, specialty CRO providing full scope services and guidance based on robust scientific experience. I look forward to helping further shape the company's strategic path forward."

About ProSciento, Inc.
ProSciento is a full scope clinical R&D services provider, exclusively focused on diabetes, NASH and obesity. The company has completed more than 250 metabolic clinical projects, representing more early phase type 1 and type 2 diabetes clinical trials than any other U.S. provider.¹  The team has supported the development of more than 15 metabolic drugs and devices on the market worldwide.

The company works with clients worldwide to support their metabolic drug and device candidates as an intellectual partner to develop and implement strategies from IND/CTA and NDA/ANDA filing to post-market and investigator initiated studies, including clinical development, regulatory, licensing and partnering support. For more information, visit www.prosciento.com.

¹ Comparative data from Citeline SiteTrove, a service provided by Informa Pharma Intelligence, April 2016

SOURCE ProSciento, Inc.

Related Links

http://prosciento.com/